AUTHOR INDEX

Volume 64 • 1994

Ahmed, M.M. *See* Al-Harbi, M.M.
Akai, T. *See* Ozawa, M.
Al-Harbi, M.M., Qureshi, S., Ahmed, M.M., Raza, M., Miana, G.A. and Shah, A.H.
Antiinflammatory activity of santonin 135
Ando, K., Miyata, H. and Yanagita, T.
Discriminative effects of methamphetamine 35
Arai, H., Nakagawa, M., Tanada, K., Yamaguchi, H. and Hirai, S.
Atrial histamine H_2-antagonism by T-593 251
Arakawa, H. *See* Maeda, N.

Chen, D.-Z. *See* Ohkuma, S.
Chen, S.-H. *See* Ohkuma, S.
Chiba, S. *See* Ren, L.-M.

Egashira, T. *See* Kouno, T.
—— *See* Takayama, F.

Fujimoto, S. *See* Tsushima, H.

Gomi, Y. *See* Suzuki, N.

Hara, H. *See* Morimoto, Y.
Hasegawa, T. *See* Hayashi, T.
Hashimoto, H., Imamura, S., Ikeda, K. and Nakashima, M.
Interaction of antiarrhythmic drugs 235
Hata, Y. *See* Kimura, I.
Hayashi, T., Yamada, K., Hasegawa, T., Ishihara, S., Kameyama, T., Morimasa, T., Kaneyuki, T., Shohmori, T. and Nabeshima, T.
Effect of *Kamikihito* on receptor binding 303
Hirai, S. *See* Arai, H.
Hisada, Y. *See* Suzuki, K.
Hustveit, O.
Muscarinic receptor binding of opiates 57

Ichida, S., Wada, T., Matsuda, N. and Nakazaki, S.
Effects of Ca channel agonists 209
Ikeda, K. *See* Hashimoto, H.
Ikegaya, Y., Saito, H. and Matsuki, N.
Carbon monoxide and LTP 225
Imamura, S. *See* Hashimoto, H.
Inoue, H. *See* Shinohara, M.
Inoue, O. *See* Nishizawa, K.
Ishida, R. *See* Ogiku, N.
Ishihara, S. *See* Hayashi, T.
Ishii, A. *See* Kishibayashi, N.
Ishikawa, H. *See* Matsui, T.
Islam, M.A. *See* Kimura, I.
Isosaki, M., Minami, N. and Nakashima, T.
Protein kinase C and secretion 217
Ito, K. *See* Naganobu, K.
Ito, M. *See* Taniguchi, H.
Iwata, N. *See* Kozuka, M.

Kameda, Y. *See* Kimura, I.
Kameyama, T. *See* Hayashi, T.
Kaneyuki, T. *See* Hayashi, T.
Karasawa, A. *See* Kishibayashi, N.
—— *See* Nagashima, K.
—— *See* Yao, K.
Katsura, M. *See* Ohkuma, S.
Katsuta, K. *See* Nakanishi, H.
Kimura, I., Hata, Y., Islam, M.A. and Kimura, M.
NDGA inhibits diabetic $PGF_{2\alpha}$-response 65
Kimura, I., Nakano, Y., Naitoh, T., Okabe, M. and Kimura, M.
GK rat-diabetic plasma, SMC-DNA synthesis 195
Kimura, I., Nakashima, N., Komori, T., Kameda, Y. and Kimura, M.
CCK-insulin release and glucose analogues 103
Kimura, M. *See* Kimura, I.
Kishibayashi, N., Ishii, A. and Karasawa, A.
Enhancement of ACh release by KW-5092 289
Kobayashi, F. *See* Matsui, T.
Kobayashi, K. *See* Kozuka, M.
Koide, T. *See* Nakanishi, H.
Kojima, R. *See* Taniguchi, H.
Komori, T. *See* Kimura, I.
Kouno, T., Egashira, T., Takayama, F., Kudo, Y. and Yamanaka, Y.
Methylprednisolone in endotoxemia 163
Kozuka, M., Kobayashi, K. and Iwata, N.
Effects of RS-8359 on postischemic LCGU 257
Kudo, Y. *See* Kouno, T.
Kuno, S. *See* Ozawa, M.
Kuribara, H.
Behavioral effects of 5-HT_{1A} agonists 273
Kuriyama, K. *See* Ohkuma, S.
Kusaka, H. *See* Nagashima, K.
—— *See* Yao, K.

Maeda, N., Matsuoka, N., Yamazaki, M., Arakawa, H., Ohkubo, Y. and Yamaguchi, I.
A screening based on a hypothesis 147
Masukawa, T. and Nakanishi, K.
DEDC and alloxan diabetes 141
Matsuda, K., Niitsuma, A., Uchida, M.K. and Suzuki-Nishimura, T.
Inhibition by lectins on secretion 1
Matsuda, N. *See* Ichida, S.
Matsuda, T. *See* Tsushima, H.
Matsui, T., Nakamura, Y., Ishikawa, H., Matsuura, A. and Kobayashi, F.
Novel aldose reductase inhibitor, SPR-210 115
Matsuki, N. *See* Ikegaya, Y.
—— *See* Okada, F.
Matsumoto, A. *See* Suzuki, K.
Matsuoka, N. *See* Maeda, N.
Matsuura, A. *See* Matsui, T.
Miana, G.A. *See* Al-Harbi, M.M.
Minami, N. *See* Isosaki, M.
Miyata, H. *See* Ando, K.
Miyata, T. *See* Shinohara, M.
Mizuno, K. *See* Suzuki, N.
Mizuta, E. *See* Ozawa, M.
Morimasa, T. *See* Hayashi, T.
Morimoto, Y., Oshima, S., Hara, H. and Sukamoto, T.
Effect of KB-5492 on gastric cell damage 41
Morimoto, Y., Shimohara, K., Oshima, S., Hara, H. and Sukamoto, T.

Effects of KB-5492 on gastric barrier 49
Morimoto, Y., Shimohara, K., Tanaka, K., Hara, H. and Sukamoto, T.
Effects of KB-5492 on cysteamine-ulcers 221
Morohashi, T., Sano, T. and Yamada, S.
Sr effects at various doses 155

Nabeshima, T. *See* Hayashi, T.
Nagamatsu, T. *See* Taniguchi, H.
Naganobu, K. and Ito, K.
Role of SR in resistance arteries 89
Nagashima, K., Kusaka, H., Sato, K. and Karasawa, A.
Renal effects of adenosine A_1-antagonist 9
Naitoh, T. *See* Kimura, I.
Nakada, Y. *See* Ozawa, M.
Nakagawa, M. *See* Arai, H.
Nakamura, Y. *See* Matsui, T.
Nakane, T. *See* Ren, L.-M.
Nakanishi, H., Katsuta, K., Koide, T., Ueda, Y., Shirakawa, K. and Yoshida, K.
NMDA antagonist, FR115427 and ischemia 189
Nakanishi, K. *See* Masukawa, T.
Nakano, Y. *See* Kimura, I.
Nakashima, M. *See* Hashimoto, H.
Nakashima, N. *See* Kimura, I.
Nakashima, T. *See* Isosaki, M.
Nakazaki, S. *See* Ichida, S.
Narita, H. *See* Ogiku, N.
Niitsuma, A. *See* Matsuda, K.
Nishimura, T. *See* Ogiku, N.
Nishio, A. *See* Sakaguchi, H.
Nishizawa, K., Inoue, O., Saito, Y. and Suzuki, A.
Effects of *Kamikihi-To* against ischemia 171

Ogata, K. *See* Shinohara, M.
Ogiku, N., Sumikawa, H., Nishimura, T., Narita, H. and Ishida, R.
Imidapril on (NZW × BXSB)F1 mice 129
Ohkubo, Y. *See* Maeda, N.
Ohkuma, S., Chen, S.-H., Katsura, M., Chen, D.-Z. and Kuriyama, K.
Muscimol protects neuronal death by NMDA 125
Ohura, K. *See* Shinohara, M.
Okabe, M. *See* Kimura, I.
Okada, F., Torii, Y., Saito, H. and Matsuki, N.
Antiemetic effect of 5-HT_{1A} agonists 109
Okamoto, H. *See* Wang, E.
Orito, K., Yanagisawa, T. and Taira, N.
TBA and K_{ATP} opened by levcromakalim 297
Oshima, S. *See* Morimoto, Y.
Ozawa, M., Nakada, Y., Sugimachi, K., Yabuuchi, F., Akai, T., Mizuta, E., Kuno, S. and Yamaguchi, M.
Abecarnil, anxiolytic β-carboline 179

Qureshi, S. *See* Al-Harbi, M.M.

Raza, M. *See* Al-Harbi, M.M.
Ren, L.-M., Nakane, T. and Chiba, S.
Reactivity of splenic artery 19

Saito, H. *See* Ikegaya, Y.
—— *See* Okada, F.
—— *See* Shitaka, Y.
Saito, Y. *See* Nishizawa, K.
Sakaguchi, H. and Nishio, A.
Ca^{2+} channels during Mg-deficiency 265
Sakurai, K. and Yamasaki, K.
Protection from H_2O_2 by rebamipide 229
Sano, J. *See* Yao, K.
Sano, T. *See* Morohashi, T.
Sato, K. *See* Nagashima, K.
—— *See* Yao, K.
Shah, A.H. *See* Al-Harbi, M.M.
Shimohara, K. *See* Morimoto, Y.
Shinohara, M., Ohura, K., Ogata, K., Inoue, H., Miyata, T. and Yoshioka, M.
Sialic acid and gingivitis 61
Shirakawa, K. *See* Nakanishi, H.
Shitaka, Y. and Saito, H.
Effect of bFGF on transplanted neurons 27
Shohmori, T. *See* Hayashi, T.
Sugimachi, K. *See* Ozawa, M.
Sukamoto, T. *See* Morimoto, Y.
Sumikawa, H. *See* Ogiku, N.
Suzuki, A. *See* Nishizawa, K.
Suzuki, K., Yoshimura, Y., Hisada, Y. and Matsumoto, A.
Regulation of intestinal ALP inhibition 97
Suzuki, N., Mizuno, K. and Gomi, Y.
NK_2-mediated "off" contraction 213
Suzuki, Y. *See* Taniguchi, H.
Suzuki-Nishimura, T. *See* Matsuda, K.

Taira, N. *See* Orito, K.
Takano, M. *See* Wang, E.
Takayama, F. *See* Kouno, T.
Takayama, F., Egashira, T. and Yamanaka, Y,
Diclofenac in liver ischemia-reperfusion 71
Tanada, K. *See* Arai, H.
Tanaka, K. *See* Morimoto, Y.
Taniguchi, H., Nagamatsu, T., Kojima, R., Ito, M. and Suzuki, Y.
Antinephritic effect of MPS 79
Torii, Y. *See* Okada, F.
Tsushima, H., Fujimoto, S. and Matsuda, T.
β-Adrenoceptors in the PVN of SHR 201

Uchida, M.K. *See* Matsuda, K.
Ueda, Y. *See* Nakanishi, H.

Wada, T. *See* Ichida, S.
Wang, E., Yayama, K., Takano, M. and Okamoto, H.
Angiotensinogen in rat urine 243

Yabuuchi, F. *See* Ozawa, M.
Yamada, K. *See* Hayashi, T.
Yamada, S. *See* Morohashi, T.
Yamaguchi, H. *See* Arai, H.
Yamaguchi, I. *See* Maeda, N.
Yamaguchi, M. *See* Ozawa, M.
Yamanaka, Y, *See* Takayama, F.
—— *See* Kouno, T.
Yamasaki, K. *See* Sakurai, K.
Yamazaki, M. *See* Maeda, N.
Yanagisawa, T. *See* Orito, K.
Yanagita, T. *See* Ando, K.
Yao, K., Kusaka, H., Sano, J., Sato, K. and Karasawa, A.
Diuretic effects of KW-3902 281
Yayama, K. *See* Wang, E.
Yoshida, K. *See* Nakanishi, H.
Yoshimura, Y. *See* Suzuki, K.
Yoshioka, M. *See* Shinohara, M.

SUBJECT INDEX

Volume 64 • 1994

Abecarnil 179
Acetylcholine release 289
Acute renal failure 281
Adenosine A_1-receptor antagonist 9, 281
Adrenal medulla 217
α-Adrenoceptor 19
α_1-Adrenoceptor 89
β-Adrenoceptor subtype 201
Aldose reductase inhibitor 115
Alkaline phosphatase inhibition 97
Ambulatory activity 273
Analgesic 135
Androgen 243
Angiotensinogen 243
Angiotensinogen mRNA 243
Anoxia 171
Antiarrhythmic drug (class I) 235
Antidiuretic effect 201
Anti-GBM nephritis 79
Antiinflammatory 135
Antipyretic 135
Anti-ulcer agent 41
Anxiolytic 179
Aspirin 49
ATP-sensitive K^+ (K_{ATP}) channel 297
Atrium (guinea pig) 251

Basic fibroblast growth factor (bFGF) 27
Benzodiazepine 179
Bicarbonate secretion 221

Ca agonist 209
^{45}Ca uptake (KCl-stimulated) 209
Calcium 155
β-Carboline 179
Cholecystokinin-8 (CCK-8) 103
Circular muscle (guinea pig ileum) 213
Cisplatin 109
Clonidine 19
Conflict behavior 273
Corticosterone 195
Cyclooxygenase 65
Cyclopiazonic acid 89

Daily administration 79
Diabetes (alloxan-induced) 141
Diabetic mesenteric vein and artery 65
Diabetic neuropathy 115
Diabetic plasma (GK rat) 195
Diabetic retinopathy 115
Diethyldithiocarbamate 141
Differentiation 209
Disulfiram 141
Diuretic effect 9, 281
DNA synthesis 195
Dopamine 35
Drug discrimination 35
Drug interaction 273

Electroretinogram 115
Emesis 109

Fentanyl 57
FR115427 ((+)-1-methyl-1-phenyl-1,2,3,4-tetrahydro-isoquinoline hydrochloride) 189
FR121196 (*N*-[4-acetyl-1-piperazinyl]-4-fluorobenzensulfonamide) 147
Free radical (oxygen-derived) 71

GABA 179
$GABA_A$-receptor agonist 125
Gastric epithelial cell 41
Gastric mucosal barrier 49
Gastric mucosal lesion 229
Gastric mucosal protection 41
Gastric mucus 49
Gastric transmucosal potential difference 49
Gingivitis 61
Glutathione 229

H7 (1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride) 265
Heme oxygenase inhibitor 225
Hippocampal damage 189
Hippocampus 147, 225
Histamine H_2-antagonist 251
Histamine release 1
H_2O_2 229
L-Homoarginine 97
5-HT_{1A} agonist 273
5-HT_{1A} receptor 109
Hypoxia 171

Ileum (guinea pig) 289
Imidapril 129
Insulin 195
Insulin release 103
Intermittent administration 79
Ischemia 171, 189, 257
Ischemia-reperfusion injury 71
Islet (rat perifused) 103

Kamikihi-To 171
Kamikihito 303
KB-5492 (4-methoxyphenyl 4-(3,4,5-trimethoxybenzyl)-1-piperazineacetate monofumarate monohydrate) 41, 49, 221
Kinetics 155
KW-3902 (8-(noradamantan-3-yl)-1,3-dipropylxanthine) 9, 281
KW-5092 ({1-[2-[[[5-(piperidinomethyl)-2-furanyl]methyl]amino]ethyl]-2-imidazolidinylidene}propanedinitrile fumarate) 289

Lectin 1
Levcromakalim 297
Lipid peroxidation 71, 163
Lipopolysaccharide 163
Lipoxygenase 65
Lipoxygenase inhibitor 65
Local cerebral glucose utilization (LCGU) 257

Mast cell 1
Memory 147
Methamphetamine 35
N-Methyl-D-aspartate (NMDA) 189
N-Methyl-D-aspartate (NMDA) receptor 125
N-Methyl-D-aspartic acid 171
Methylprednisolone 163
Methylprednisolone suleptanate 79
Mg-deficient rat 265
MK801 ((+)-5-methyl-10,11-dihydro-5*H*-dibenzo(*a*,*d*)cyclohepten-5,10-imine) 189
Motion sickness 109
Motor nerve conduction velocity 115
Muscarinic receptor 57
Myenteric plexus 289
Myocardial infarction 129, 235

Nerve growth factor (NGF) 27
Neurogenic "off" contraction 213
Neuronal injury 125
Nifedipine 265
NK_2-receptor 213
Non-immunologic stimuli 1
Non-steroidal anti-inflammatory drug 71
Noradrenaline 35
Nucleus accumbens 35
(NZW × BXSB)F1 male mice 129

Pancreas (rat perfused) 103
Paraventricular nucleus 201
Penile erection 147
Periarterial nerve stimulation 19
Pethidine 57
Phenylephrine 265
Phosphatidylcholine hydroperoxide 71
Plasma phosphatidylcholine hydroperoxide 163
[^{3}H]PN200-110 binding 265
Polymorphonuclear leukocyte 163
Positive chronotropic response 251
Positive cooperativity 97
Prostaglandin 41
Prostaglandin $F_{2\alpha}$ response 65
Protein kinase C 217
Pseudo-α-D-glucose 103

[^{3}H]QNB (quinuclidinyl benzilate) binding 303

Reactive oxygen 229
Rebamipide 229
Renal protective effect 9
Resistance vessel 89
RS-8359 ((±)-4-(4-cyanoanilino)-7-hydroxy-

cyclopenta(3,2-*e*)pyrimidine) 257
Ryanodine 89

Saliva 61
Santonin 135
Sarcoplasmic reticulum 89
Secretion 217
Septum 27
Sexual difference 243
Sialic acid 61
Smooth muscle cell (rat aorta) 195
Sodium dodecyl sulfate 97
Somatostatin 147
Splenic artery (canine) 19
Spontaneously hypertensive rat 201
Strontium 155
Subunit-subunit interaction 97
Sugar-specificity 1
SUN 8399 (4-{4-[4-(2-pyrimidinyl)piperazin-1-yl]butyl}-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione HCl) 273
Suncus 109

T-593 ((±)-*N*-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-*N'*-[2-[[[5-(methylamino)-methyl-2-furyl]methyl]thio]ethyl]-*N''*-(methylsulfonyl) guanidine) 251
[^{3}H]TCP (*N*-(1-[2-thienyl]cyclohexyl)-3,4-piperidine) binding 303
Tetraalkylammonium ion 297
Transplantation 27

Ulcer (cysteamine-induced) 221
Unsurmountable antagonism 251
Urine 243

Vasoconstriction 19
Vasopressin 201
Ventricular activation 235
Volatile anesthetic 235

Zinc protoporphyrin IX 225